Gowling WLG acts for AstraZeneca on drug collaboration

1 minute read
18 May 2018

In July 2017, AstraZeneca completed a transaction on a cancer drug collaboration with Merck. Merck will pay AstraZeneca up to $8.5 billion in total consideration, including $1.6 billion upfront, $750 million for certain license options and up to $6.15 billion contingent upon successful achievement of future regulatory and sales milestones. Gowling WLG acted for AstraZeneca on this transaction.

The companies will develop and commercialise Lynparza jointly, both as monotherapy and in combination with other potential medicines.

The team at Gowling WLG acted for AstraZeneca and included Patrick Duxbury, Luke Kempton, Jenny Davies, Chris Freeth, Mathilda Davidson and Ammina Rao plus Jeremy Millington in corporate. The AstraZeneca in house legal team was led by Deputy General Counsel Liam McIlveen and Senior Counsel Matt Chuter.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.